Abstract: A red-light emitting device comprising: a blue LED chip; and a photoluminescence material comprising a narrowband red fluoride phosphor and a broadband red phosphor. The narrowband red phosphor may comprise a manganese-activated fluoride phosphor of composition K2SiF6:Mn4+, K2GeF6:Mn4+, and K2TiF6:Mn4+.

Abstract: Disclosed herein are compounds of formula (I), and/or a stereoisomer, a stable isotope, or a pharmaceutically acceptable salt or solvate thereof; and therapeutic uses of these compounds, which are inhibitors of SHP2, potentially useful in the treatment of SHP2-associated diseases, such as SHP2-associated cancers.

Abstract: A resilient cutting member includes an elongated metal support body and an elongated metal blade. The metal support includes an elongated platform portion supporting the metal blade from below; a blade edge of the metal razor blade is located directly front of and above the platform portion; a first position and a second position spaced apart in a length direction of the metal blade are respectively fixed with the platform portion, the length of a free section, located between the first position and the second position, of the metal blade is greater than or equal to 10 mm and less than or equal to 30 mm, and the free section makes reversible bending deformation with respect to the platform portion, so that the cutting member more tightly fits to the skin, and shaving is cleaner.

Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: A vehicle frame applied to a baby stroller includes a first tube, a second tube, a third tube and a foldable unit. The second tube is pivoted to the first tube. The third tube is pivoted to the second tube. The foldable unit includes a fourth tube. An end of the fourth tube is pivoted to the first tube, and the other end of the fourth tube is pivoted to the third tube. A linkage mechanism is formed by the first tube, the second tube, the third tube and the fourth tube. Rotation of the first tube moves the second tube and the third tube close to each other or away from each other via the fourth tube for folding or unfolding the vehicle frame. The present invention can simultaneously fold all tubes of the vehicle frame, and have advantages the simple structure, easy operation and low production cost.

Abstract: This invention provides a UV spectroscopy apparatus and method for controlled drug waste diversion detection. The spectroscopy apparatus employs sample cells which have optimized optical path length such that the measured maximum absorbance of the drug is less than the detection limit of the system. Hence the full unsaturated absorption spectrum of the drug is revealed in the UV wavelength region from 230 nm (or even down to 195 nm) to 400 nm. This full spectrum analysis improves the specificity for drug identification and the accuracy for drug concentration verification. The spectral library of the apparatus comprises the spectra of common controlled drugs, excipients, as well as typical diluents, which enables the identification of controlled drugs from different manufacturers and/or diluted with different types of diluents.

Abstract: A device may include a broadband LED flip chip that generates broadband light of dominant wavelength from about 420 nm to about 480 nm and a FWHM from 25 nm to 50 nm; and at least one photoluminescence layer covering a light emitting face of the broadband LED flip chip; wherein the broadband LED flip chip comprises a broadband InGaN/GaN multiple quantum wells LED chip comprising multiple different wavelength quantum wells in its active region that generate multiple narrowband light emissions of multiple different wavelengths, where broadband light generated by the broadband LED flip chip includes a combination of the multiple narrowband light emissions, and where at least one photoluminescence material layer comprises a first photoluminescence material which generates light with a peak emission wavelength from 490 nm to 550 nm; and a second photoluminescence material which generates light with a peak emission wavelength from 600 nm to 680 nm.

Abstract: The present invention relates to salt forms of the Fibroblast Growth Factor Receptors (FGFR) inhibitor 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3?,2?:5,6]pyrido[4,3-d] pyrimidin-2-one, including methods of preparation thereof, where the compound is useful in the treatment of FGFR mediated diseases such as cancer.

Abstract: The present application relates to the technical field of mobile communication and discloses a resource scheduling method, a base station, a user equipment (UE), an electronic device and a storage medium. The resource scheduling method is applied to the base station and includes: selecting schedulable resource symbols from the resource symbols in a reserved slot according to interference situation of resource symbols in the reserved slot; selecting several resource symbols from the schedulable resource symbols and generating resource scheduling information of the UE according to uplink and/or downlink throughput requirements of the UE, during a scheduling cycle of the UE; and sending the resource scheduling information to the UE. The resource scheduling information includes information indicating that the several resource symbols are adjusted to uplink and/or downlink resource symbols of the UE.

Abstract: A light emitting device includes a Chip Scale Packaged (CSP) LED, the CSP LED including an LED chip that generates blue excitation light; and a photoluminescence layer that covers a light emitting face of the LED chip, wherein the photoluminescence layer comprises from 75 wt % to 100 wt % of a manganese-activated fluoride photoluminescence material of the total photoluminescence material content of the layer. The device/CSP LED can further include a further photoluminescence layer that covers the first photoluminescence and that includes a photoluminescence material that generates light with a peak emission wavelength from 500 nm to 650 nm.

Abstract: An exemplary white light emitting device includes a plurality of LEDs disposed on a substrate, where the LEDs emit blue light at substantially the same correlated color temperature; a first photoluminescence material layer disposed over a first subset of the LEDs; a second photoluminescence material layer disposed over a second subset of the LEDs different from the first subset of the plurality of LEDs, the second photoluminescence material layer separate from the first photoluminescence material layer; and a diffusing layer separate from and disposed over the first and second photoluminescence layers, where the diffusing layer is associated with a plurality of light scattering particles.

Abstract: A video playing method and apparatus are provided. The method may include transmitting a scenario obtaining request. The scenario obtaining request may be for requesting to obtain scenario information of a first scenario video. The scenario information may include a video address of the first scenario video and n scenario development options. The method may further include playing the first scenario video according to the video address of the first scenario video, obtaining scenario video data corresponding to the n scenario development options during playing the first scenario video, and adding the scenario video data corresponding to the n scenario development options into a buffer list. The method may further include obtaining scenario video data of a second scenario video from the buffer list and playing the second scenario video in response to receiving a selection instruction for a target scenario development option in the n scenario development options.

Abstract: The present invention relates to salt forms of the Pim kinase inhibitor N—{(7R)-4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of Pim kinase-related diseases such as cancer.

Abstract: The present disclosure provides novel crystalline forms of a compound that acts as a CDK9 modulator, processes for preparing the novel crystalline forms of a compound that acts as a CDK9 modulator, and uses thereof.

Abstract: The present application provides salt forms of N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-Amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which are useful as inhibitors of TAM kinases, as well as processes and intermediates related thereto.

Abstract: The present disclosure relates to 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3?,2?:5,6]pyrido[4,3-d]pyrimidin-2-one, solid forms and polymorphs thereof, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.

Abstract: A child carrier includes a supporting frame, a sliding base, and a seat. The sliding base is disposed on the supporting frame and slidable in a substantially longitudinal direction of the supporting frame. The seat is foldably assembled with the sliding base. The seat includes a seat portion, a handrail base and a link member, and the link member, the seat portion, the handrail base and the sliding base cooperatively form a four bar linkage mechanism for performing a folding motion.

Abstract: A full spectrum light emitting device includes photoluminescence materials which generate light with a peak emission wavelength in a range 490 nm to 680 nm (green to red) and a broadband solid-state excitation source operable to generate broadband blue excitation light with a dominant wavelength in a range from 420 nm to 470 nm, where the broadband blue excitation light includes at least two different blue light emissions in a wavelength range 420 nm to 480 nm.

Abstract: An exemplary light emitting device includes a solid-state light emitter which generates blue excitation light with a dominant wavelength from 440 nm to 470 nm; a yellow to green photoluminescence material which generates light with a peak emission wavelength from 500 nm to 575 nm; a broadband orange to red photoluminescence material which generates light with a narrowband peak emission wavelength from 580 nm to 620 nm; and a narrowband red manganese-activated fluoride phosphor which generates light with a peak emission wavelength from 625 nm to 635 nm. The device generates white light with a spectrum having a broad emission peak from about 530 nm to about 600 nm and a narrow emission peak and where the ratio of the peak emission intensity of the broad emission peak to the peak emission intensity of the narrow emission peak is at least 20%.

Abstract: The present disclosure provides a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and therapeutic uses of these compounds. They are kinase inhibitors potentially useful in the treatment of diseases treatable, such as cancers. Also disclosed herein is a pharmaceutical composition, comprising a compound of Formula (I) and/or a stereoisomer, a tautomer, a stable isotope, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.